

Ancuceanu R, Dinu M, Furtunescu F, Boda D. An inventory of medicinal products causing skin rash: Clinical and regulatory lessons. *Exp Ther Med.* 2019 Dec;18(6):5061-5071. doi: 10.3892/etm.2019.7837. Epub 2019 Jul 31.

Bailey J, Thew M, Balls M. An analysis of the use of dogs in predicting human toxicology and drug safety. *Altern Lab Anim.* 2013 Nov; 41(5):335-50.

Basilua JM, Pochart P. Cotrimoxazole Prophylaxis Is Not Associated with a Higher occurrence of Atazanavir Treatment Failure: analysis of Worldwide Pharmacovigilance Data. *Infect Disord Drug Targets.* 2019 Dec 19. doi: 10.2174/1871526520666191220112416. [Epub ahead of print] PMID: 31858913

Calderón MA, Rodríguez Del Río P, Vidal C, Just J, Pfaar O, Linneberg A, Demoly P. An EAACI "European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI)": the methodology. *Clin Transl Allergy.* 2014 Jul 21; 4:22.

Cannon JA, Shen L, Jhund PS, Kristensen SL, Køber L, Chen F, Gong J, Lefkowitz MP, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJ; PARADIGM-HF Investigators and Committees. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. *Eur J Heart Fail.* 2016 Nov 20.

Chen W, Zhao N, Qin G, Chen J. A Bayesian group sequential approach to safety signal detection. *J Biopharm Stat.* 2013; 23(1):213-30.

Chung S, Williams B, Dobrinsky C, Patten A, Yang H, Laurenza A. Perampanel with concomitant levetiracetam and topiramate: Post hoc analysis of adverse events related to hostility and aggression. *Epilepsy Behav.* 2017 Aug 19; 75:79-85.

Colombel JF, Sandborn WJ, Reinisch W, Peyrin-Biroulet L, Panaccione R, Rutgeerts P, Hanauer SB, Ghosh S, Van Assche G, Robinson AM, Lau W, Maa JF, Huang B, Pappalardo B, Read H. Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. *Aliment Pharmacol Ther.* 2017 Nov 21.

Coro JL, Carrillo T, Pedemonte C, Plaza Martin AM, Martín Hurtado S, Dige E, Calderon MA. Tolerability during double-blind randomized phase I trials with the house dust mite allergy immunotherapy tablet in adults and children. *J Investig Allergol Clin Immunol.* 2014; 24(3):154-61.

Crépin S, Villeneuve C, Merle L. Quality of serious adverse events reporting to academic sponsors of clinical trials: far from optimal. *Pharmacoepidemiol Drug Saf.* 2016 Feb 17.

Cullinan MP, Palmer JE, Carle AD, West MJ, Westerman B, Seymour GJ. The influence of a triclosan toothpaste on adverse events in patients with cardiovascular disease over 5-years. *Sci Total Environ.* 2014 Nov 28.

Dayan GH, Galán-Herrera JF, Forrat R, Zambrano B, Bouckennooghe A, Harenberg A, Guy B, Lang J. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.

de Vries ST, Mol PG, de Zeeuw D, Haaijer-Ruskamp FM, Denig P. Development and Initial Validation of a Patient-Reported Adverse Drug Event Questionnaire. *Drug Saf.* 2013 Apr 4.

Dovey SM, Leitch S, Wallis KA2, Eggleton KS, Cunningham WK, Williamson MI, Lillis S, McMenamain AW, Tilyard MW, Reith DM5, Samaranayaka A, Hall JE. Epidemiology of Patient Harms in New Zealand: Protocol of a General Practice Records Review Study. *JMIR Res Protoc.* 2017 Jan 24; 6(1):e10.

Endo S, Shimazaki R; Antithrombin Gamma Study Group. An open-label, randomized, phase 3 study of the efficacy and safety of antithrombin gamma in patients with sepsis-induced disseminated intravascular coagulation syndrome. *J Intensive Care.* 2018 Nov 16; 6:75. doi: 10.1186/s40560-018-0339-z. eCollection 2018.

Ettinger AB, LoPresti A, Yang H, Williams B, Zhou S, Fain R, Laurenza A. Psychiatric and behavioral adverse events in randomized clinical studies of the noncompetitive AMPA receptor antagonist perampanel. *Epilepsia.* 2015 Jul 3.

Finnell JS, Saul BC, Goldhamer AC, Myers TR. Is fasting safe? A chart review of adverse events during medically supervised, water-only fasting. *BMC Complement Altern Med.* 2018 Feb 20; 18(1):67.

Fizazi K, Chi KN, de Bono JS, Gomella LG, Miller K, Rathkopf DE6Ryan CJ, Scher HI, Shore ND, De Porre P, Londhe A, McGowan T, Pelhivanov N, Charnas R, Todd MB, Montgomery B. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. *Eur Urol.* 2016 Mar 7.

Fredlund P, Hillson J, Gray T, Shemanski L, Dimitrova D, Srinivasan S. Peginterferon Lambda-1a is Associated with a Low Incidence of Autoimmune Thyroid Disease in Chronic Hepatitis C. *J Interferon Cytokine Res.* 2015 Sep 16.

Gopal S, Hough D, Karcher K, Nuamah I, Palumbo J, Berlin JA, Baseman A, Xu Y, Kent J. Risk of cardiovascular morbidity with risperidone or paliperidone treatment: analysis of 64 randomized, double-blind trials. *J Clin Psychopharmacol.* 2013 Apr; 33(2):157-61.

Hefter H, Benecke R, Erbguth F, Jost W, Reichel G, Wissel J. An open-label cohort study of the improvement of quality of life and pain in de novo cervical dystonia patients after injections with 500 U botulinum toxin A (Dysport). *BMJ Open.* 2013 Apr 18; 3(4).

Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, Hupperts R, Blight AR, Englishby V, McNeill M, Chang I, Lima G, Elkins J, ENHANCE study investigators. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine. *CNS Drugs.* 2018 Dec 10. doi: 10.1007/s40263-018-0586-5.

Isojarvi J, Lee D, Peng G, Sperling MR. Clobazam-treated patients with Lennox-Gastaut syndrome experienced fewer seizure-related injuries than placebo patients during trial OV-1012. *Epilepsia.* 2016 May 4.

Jayawardena S, Leyva R, Kellstein D. Safety of a novel formulation of ibuprofen sodium compared with standard ibuprofen and placebo. *Postgrad Med.* 2014 Dec 15:1-5.

Kalaivani M, Singh A, Kalaiselvan V. Therapeutic monoclonal antibodies and the need for targeted pharmacovigilance in India. *MAbs.* 2015 Jan 2; 7(1):276-80.

Kelly K, Infante JR, Taylor MH, Patel MR, Wong DJ, Iannotti N, Mehnert JM, Loos AH, Koch H, Speit I8, Gulley JL. Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials. *Cancer.* 2018 Feb 22.

Laubach JP, Moslehi JJ, Francis SA, San Miguel JF, Sonneveld P, Orłowski RZ, Moreau P, Rosiñol L, Faber EA Jr, Voorhees P, Mateos MV, Marquez L, Feng H, Desai A, van de Velde H, Elliott J, Shi H, Dow E, Jobanputra N, Esseltine DL, Niculescu L, Anderson KC, Lonial S, Richardson PG. A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in

multiple myeloma. *Br J Haematol.* 2017 May 3.

Lavonas EJ, Banner W, Bradt P, Bucher-Bartelson B, Brown KR, Rajan P, Murrelle L, Dart RC, Green JL. Root Causes, Clinical Effects, and Outcomes of Unintentional Exposures to Buprenorphine by Young Children. *J Pediatr.* 2013 Nov; 163(5):1377-83.

Lopez P, Kohler S, Dimri S. Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature. *J Transplant.* 2014; 2014:305931.

Lu MJ, Liu YX. MedDRA and its applications in statistical analysis of adverse events. *Yao Xue Xue Bao.* 2015 Nov; 50(11):1396-401. (in Chinese only)

Maund E, Tendal B, Hróbjartsson A, Lundh A, Gøtzsche PC. Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study. *BMJ.* 2014 Jun 4; 348:g3555.

McEvoy BW, Nandy RR, Tiwari RC. Bayesian approach for clinical trial safety data using an ising prior. *Biometrics.* 2013 Jul 11.

McNeil MM, Cano M, Miller E, Petersen BW, Engler RJ, Bryant-Genevier MG. Ischemic cardiac events and other adverse events following ACAM2000® smallpox vaccine in the vaccine adverse event reporting system. *Vaccine.* 2014 Jun 18.

Melia MT, Bräu N, Poordad F, Lawitz EJ, Shiffman ML, et al. Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: Results of the IDEAL study. *Clin Infect Dis.* 2014 Jan 6.

Min KC, Woo T, Assaid C, McCrea J, Gurner DM, Sisk CM, Adkinson F, Herring WJ. Incidence of hypersensitivity and anaphylaxis with sugammadex. *J Clin Anesth.* 2018 Apr 2; 47:67-73.

Miravittles M, Price D, Rabe KF, Schmidt H, Metzdorf N, Celli B. Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis.* 2015 Mar 16; 10:549-64. 2015.

Moja L, Lucenteforte E, Kwag KH, Bertele V, Campomori A, Chakravarthy U, D'Amico R, Dickersin K, Kodjikian L, Lindsley K, Loke Y, Maguire M, Martin DF, Mugelli A, Mühlbauer B, Püntmann I, Reeves B, Rogers C, Schmucker C, Subramanian ML, Virgili G. Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration. *Cochrane Database Syst Rev*. 2014 Sep 15; 9:CD011230.

Morley R, Cardenas A, Hawkins P, Suzuki Y, Paton V, Phan SC, Merchant M, Hsu J, Yu W, Xia Q, Koralek D, Luhn P, Aldairy W. Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program. *PLoS One*. 2015 Oct 7; 10(10):e0139679.

Novitt-Moreno A, Ransom J, Dow G, Smith B, Read LT, Toovey S. Tafenoquine for malaria prophylaxis in adults: An integrated safety analysis. *Travel Med Infect Dis*. 2017 May 8.

Oviedo-Joekes E, Brissette S, MacDonald S, Guh D, Marchand K, Jutha S, Harrison S, Janmohamed A, Zhang DZ, Anis AH, Krausz M, Marsh DC, Schechter MT. Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder. *Drug Alcohol Depend*. 2017 May 10; 176:55-62.

Palermo S, Giovannelli F, Bartoli M, Amanzio M. Are Patients With Schizophrenia Spectrum Disorders More Prone to Manifest Nocebo-Like-Effects? A Meta-Analysis of Adverse Events in Placebo Groups of Double-Blind Antipsychotic Trials. *Front Pharmacol*. 2019 May 17; 10:502. doi: 10.3389/fphar.2019.00502. eCollection 2019.

Peyvandi F, Scully M, Kremer Hovinga JA, Knöbl P, Cataland S, De Beuf K, Callewaert F, De Winter H, Zeldin RK. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations, and death in patients with acquired thrombotic thrombocytopenic purpura. *J Thromb Haemost*. 2017 Apr 26.

Pivonello R, Muscogiuri G, Holder G, Paul M, Sarp S, Lesogor A, Jordaan P, Eisinger J, Colao A. Long-term safety of long-acting octreotide in patients with diabetic retinopathy: results of pooled data from 2 randomized, double-blind, placebo-controlled phase 3 studies. *Endocrine*. 2017 Nov 7.

Rabe E, Agus GB, Roztocil K. Analysis of the effects of micronised purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomised trial. *Int Angiol*. 2015 May 14.

Riedl M, Kolbe E, Kampmann E, Krämer I, Kahaly GJ. Prospectively recorded and MedDRA-coded

safety data of intravenous methylprednisolone therapy in Graves' orbitopathy. *J Endocrinol Invest.* 2015 Jan 10.

Riedl M, Kuhn A, Krämer I, Kolbe E, Kahaly GJ. Prospective, systematically recorded mycophenolate safety data in Graves' orbitopathy. *J Endocrinol Invest.* 2016 Feb 17.

Roberto G, Zanoni G. Disease-related adverse events following non-live vaccines: Investigation of a newly described reporting bias through the analysis of the WHO Global ICSR Database, VigiBase. *Vaccine.* 2013 Nov 26.

Rodríguez Del Río P, Vidal C, Just J, Tabar AI, Sanchez-Machin I, Eberle P, Borja J, Bubel P, Pfaar O, Demoly P, Calderón MA. The European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a paediatric assessment. *Pediatr Allergy Immunol.* 2016 Sep 17.

Salaets T, Turner MA, Short M, Ward RM, Hokuto I, Ariagno RL, Klein A, Beauman S, Wade K, Thomson M, Roberts E, Harrison J, Quinn T, Baer G, Davis J, Allegaert K. International Neonatal Consortium. Development of a neonatal adverse event severity scale through a Delphi consensus approach. *Arch Dis Child.* 2019 Sep 19. pii: archdischild-2019-317399. doi: 10.1136/archdischild-2019-317399.

Schmeltz LR, Blevins TC, Aronoff SL, Ozer K, Leffert JD, et al. Anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (Hashimoto's) thyroiditis: A randomized controlled clinical trial. *J Clin Endocrinol Metab.* 2014 Jan; 99(1):E137-42.

Schmitz B, Dimova S, Zhang Y, Chellun D, De Backer M, Gasalla T. Tolerability and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy and concomitant psychiatric conditions: Post hoc analysis of a prospective, randomized, double-blind trial. *Epilepsy Res.* 2019 Oct 16;159:106220. doi: 10.1016/j.epilepsyres.2019.106220.

Schoenewald S, Ross S, Bloom L, Shah M, Luch Jy, Lin CL, Patel M, Boyle K, Kuffner E. New insights into root causes of pediatric accidental unsupervised ingestions of over-the-counter medications. *Clin Toxicol (Phila).* 2013 Dec; 51(10):930-6.

Silverman SL, Wang A, Cheng L, Yang Y, Libanati C, Geller M, Grauer A, Nevitt M, Revicki D, Viswanathan HN. Comorbidity indices for clinical trials: adaptation of two existing indices for use with the FREEDOM trial in women with postmenopausal osteoporosis. *Osteoporos Int.* 2015 Jul 15.

Simon JA, Portman DJ, Kazempour K, Mekonnen H, Bhaskar S, Lippman J. Safety Profile of

Paroxetine 7.5 mg in Women With Moderate-to-Severe Vasomotor Symptoms. *Obstet Gynecol.* 2014 May; 123 Suppl 1:132S-3S.

Stainsby CM, Perger TM, Vannappagari V, Mounzer KC, Hsu RK, Henegar CE, Oyee J, Urbaityte R, Lane CE1, Carter LM, Pakes GE, Shaefer MS. Abacavir Hypersensitivity Reaction Reporting Rates During a Decade of HLA-B*5701 Screening as a Risk Mitigation Measure. *Pharmacotherapy.* 2018 Nov 10. doi: 10.1002/phar.2196.

Tetteh RA, Nartey ET, Lartey M, Mantel-Teeuwisse AK, Leufkens HG, Nortey PA, Doodoo AN. Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana. *BMC Public Health.* 2015 Jun 20; 15:573.

Trenque T, Claustre G, Herlem E, Djerada Z, Trenque A, Morel A, Azzouz B1. Methylphenidate and stuttering. *Br J Clin Pharmacol.* 2019 Aug 16. doi: 10.1111/bcp.14097.

Tweed CD, Crook AM, Dawson R, Diacon AH, McHugh TD, Mendel CM, Meredith SK, Mohapi L, Murphy ME, Nunn AJ, Phillips PP, Singh KP, Spigelman M, Gillespie SH. Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status. *BMC Pulm Med.* 2019 Aug 14; 19(1):152. doi: 10.1186/s12890-019-0907-6.

Uemura N, Kinoshita Y, Haruma K, Yao T, Kushima R, Kanoo T. Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis. *Clin Exp Gastroenterol.* 2018 Jan 24; 11:51-56.

Vaughn DW, Seifert H, Hepburn A, Dewe W, Li P, Drame M, Cohet C, Innis BL, Fries LF. Safety of AS03-adjuvanted inactivated split virion A (H1N1) pdm09 and H5N1 influenza virus vaccines administered to adults: Pooled analysis of 28 clinical trials. *Hum Vaccin Immunother.* 2014 Oct 1:1-16.

Vierling JM, Davis M, Flamm S, Gordon SC, Lawitz E, et al. Boceprevir for Chronic HCV Genotype 1 Infection in Patients with Prior Treatment Failure to Peginterferon/Ribavirin, including Prior Null Response. *J Hepatol.* 2013 Dec 19.

Ward DS, Williams MR, Berkenbosch JW, Bhatt M, Carlson D, Chappell P, Clark RM, Constant I, Conway A, Cravero J, Dahan A, Dexter F, Dionne R, Dworkin RH, Gan TJ, Gozal D, Green S, Irwin MG, Karan S, Kochman M, Lerman J, Lightdale JR, Litman RS, Mason KP, Miner J, O'Connor RE, Pandharipande P, Riker RR, Roback MG, Sessler DI, Sexton A, Tobin JR, Turk DC, Twersky RS, Urman RD, Weiss M, Wunsch H, Zhao-Wong A. Evaluating Patient-Centered Outcomes in Clinical

Trials of Procedural Sedation, Part 2 Safety: Sedation Consortium on Endpoints and Procedures for Treatment, Education, and Research Recommendations. *Anesth Analg*. 2018 May 17.

Zaccara G, Giovannelli F, Giorgi FS, Franco V, Gasparini S, Tacconi FM. Do antiepileptic drugs increase the risk of infectious diseases? A meta-analysis of placebo-controlled studies. *Br J Clin Pharmacol*. 2017 Mar 31.

Zelniker TA, Bonaca MP, Furtado R, et al. Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial [published online ahead of print, 2020 Jan 27]. *Circulation*. 2020;10.1161/CIRCULATIONAHA.119.044183. doi:10.1161/CIRCULATIONAHA.119.044183